source
- Latigo Biotherapeutics reports non-opioid drug cuts acute pain in Phase 2b trialLatigo Biotherapeutics announced that its experimental non-opioid analgesic demonstrated a reduction in acute pain in a Phase 2b clinical trial. The study results suggest the candidate may offer a…
- Apnimed secures $192 million IPO to fund sleep-apnea drug program targeting 2027 launchApnimed, a biotech focused on sleep apnea, announced it raised $192 million through an initial public offering. The capital will be used to advance its lead drug candidate, with plans to begin a l…